How three stubborn men, and $1.5 billion poured in over two decades, put India on the world’s new-drug map

Refusing to quit

What links these companies is not scale, but a grim determination to keep going despite setbacks. Glenmark’s Glenn Saldanha spent close to two decades being told his obsession with invention was destroying shareholder value. “People ... [11250 chars]